Intimation / Disclosure under regulation 30 of SEBI (LODR) Regulation 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals has appointed Mr. Yogeshkumar Prajapati (DIN 11210767) as an Additional Non-Executive Independent Director, effective August 5, 2025. The appointment is subject to shareholder approval and was recommended by the Nomination and Remuneration Committee and approved by the Audit Committee. Mr. Prajapati brings experience in management, leadership, strategic planning, and organisational growth. He is not related to any existing directors and is not debarred from holding office by SEBI or any other authority.
This is a routine governance update with no material impact on the stock. It strengthens the board with an additional independent director, which is generally positive for corporate governance. Shareholders will need to approve the appointment at a future general meeting.